Leflunomide

Rheumatic Disease Clinics of North America

Volumn 30, Issue 2, 2004, Pages 295-309

  Cannon, Grant W ^a   Kremer, Joel M ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Center for Rheumatology LLP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE;

ALOPECIA; BONE EROSION; CLINICAL TRIAL; COMPARATIVE STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL DISEASE; HEPATITIS; HUMAN; HYPERTENSION; INTERSTITIAL PNEUMONIA; LIVER INJURY; LIVER TOXICITY; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; RADIATION DETECTION; RADIODIAGNOSIS; RADIOGRAPHY; RASH; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; TUBERCULOSIS;

EID: 2542442508     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2004.01.010     Document Type: Review

References (24)

1. th edition. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 783-93.
2. Hambleton P, McMahon S. Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis. Agents Actions 1990;29:328-32.
3. Thoenes GH, Sitter T, Langer KH, Bartlett RR, Schleyerbach R. Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int J Immunopharmacol 1989;11:921-9.
4. Vidic-Dankovic B, Kosec D, Damjanovic M, Apostolski S, Isakovic K, Bartlett RR. Leflunomide prevents the development of experimentally induced myasthenia gravis. Int J Immunopharmacol 1995;17:273-81.
5. Popovic S, Bartlett RR. Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice. Agents Actions 1986;19:313-4.
6. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595-603.
7. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of rebonucleotide availability to proliferating T-lymphocyte from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 1995;270:29682-9.
8. Herrmann M, Frangou CG, Kerschbaum B. Cell cycle control of the de novo pyrimidine synthesis inhibitor leflunomide through the p53 and p21 pathways [abstract]. Arthritis Rheum 1997;40:S177.
9. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kB activation and gene expression. J Immunol 1999;162:2095-102.
10. Weber W, Harnisch L. Use of a population approach to the development of leflunomide, a new disease-modifying drug in the treatment of rheumatoid arthritis. In: Asrons L, Balant LP, KanHof M, et al, editors. European cooperation in the field of scientific and technical research. Brussels: European Commission; 1997. p. 239-44.
11. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
12. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001;44:1984-92.
13. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;43:495-505 [erratum: Arthritis Rheum 2000;43:1345].
14. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulophasalazine in active rheumatoid arthritis: a double-blind, randomized, multicenter trial. Lancet 1999;353:259-66.
15. Reece RJ, Kraan MC, Radjenovic A, Veale DJ, O'Connor PJ, Ridgway JP, et al. Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum 2002;46:366-72.
16. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996;39:1951-60.
17. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8.
18. Kremer JM, Alarcon GS, Lightfoot Jr RW. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316-28.
19. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33.
20. Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Ransford KD, Velo GP, editors. Advances in inflammation research, Volume 6. New York: Raven Press; 1984. p. 1-7.
21. Cannon GW, Schiff M, Strand V, Holden W. Hepatic adverse events and other toxicity during treatment with leflunomide, methotrexate, other disease modifying anti-rheumatic drugs, and combination DMARD therapy: comparison to NSAIDs alone and adjustment of comorbidities. Arthritis Rheum 2002;46:S166.
22. Kremer JM, Furst DE, Weinblatt ME, Blotner SD. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996;23:459-61.
23. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomer B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000;39:655-65.
24. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Weisman M, et al. Combination of leflunomide and methotrexate in patients with active rheumatoid arthritis failing MTX monotherapy: an open-label extension study. Arthritis Rheum 2001;44(Suppl):S144.